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Background: Recently, the addition of dexmedetomidine to sedation regimens after cardiac surgery had been 
reported and there is a possibility that dexmedetomidine can cause vasoconstriction. Vasopressin has been used 
as a prophylactic treatment for refractory vasodilatory shock during coronary artery bypass graft (CABG). Also, 
vasopressin may play an important role in initiating spasms at the graft artery. Here we evaluate the direct effect of 
dexmedetomidine on isolated human gastroepiploic arteries and the synergistic effect of dexmedetomidine and 
vasopressin.
Methods: Discarded gastroepiploic arteries from elective subtotal gastrectomy (n = 10) were used in this study. We 
measured the level of contraction in isolated human gastroepiploic arteries induced by increasing concentrations 
of dexmedetomidine (10
-10 to 10
-6 M) with or without vasopressin (10
-10, 10
-9 M). Arterial contractions caused by 
increasing concentrations of vasopressin (10
-10 to 10
-7.5 M) with or without dexmedetomidine (10
-9, 10
-7 M) were 
also measured in the tissue samples.
Results: Supraclinical concentrations of dexmedetomidine elicited contractions at concentrations of 10
-7 M and 
10
-6 M (P < 0.05 versus resting tension). The same concentrations of dexmedetomidine (10
-7, 10
-6 M) significantly 
enhanced vasopressin-induced contractions (P < 0.05 versus vasopressin-induced contraction). Vasopressin 
produced concentration-dependent contractions and vasopressin (10
-10, 10
-9.5, 10
-9 M) also increased the intensity 
of dexmedetomidine (10
-7 M) induced contractions.
Conclusions: There was a synergistic effect between supraclinical doses of dexmedetomidine and vasopressin on 
the degree of contraction in isolated human gastroepiploic arteries. However, a sedative dose of dexmedetomidine 
(clinical dose: 0.2-0.7 μg/kg/hr, plasma concentration: 0.36-1.25 ng/ml) did not enhance vasopressin induced-
contraction in isolated human gastroepiploic arteries. (Korean J Anesthesiol 2011; 60: 428-433)
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Introduction
    Persistent hypotension associated with low systemic vascular 
resistance and high cardiac output has been termed “vasoplegic 
syndrome” [1]. Treatment for vasoplegic syndrome involves 
inotropic support and the administration of high doses of 
vasopressors. Recent studies have reported that intravenous 
administration of vasopressin was beneficial in patients 
with persistent hypotension associated with sepsis or from 
cardiac surgeries involving cardiopulmonary bypass (CPB) [2-
4]. Vasopressin is important in the maintenance of vascular 
tone after CPB, as a deficiency in vasopressin contributes to 
vasoplegic syndrome. Both high dose (0.1 to 1 IU/min) and low 
dose (0.03 IU/min) vasopressin are effective in the treatment of 
vasoplegic syndrome after cardiac surgeries involving CPB [3,4]. 
However, vasopressin can be a strong vasoconstrictor in the 
internal thoracic and radial arteries [5], and these vessels are 
often used for coronary artery bypass grafting (CABG) [6].
    The use of dexmedetomidine (DMT) is associated with a 
reduction in the dosage of anesthetics and analgesic drugs 
used during the perioperative period, and it is also used in 
clinical practice for sedation in the ICU after cardiac operations. 
Activation of presynaptic α2-adrenoceptors on sympathetic 
nerves can lead to sympatholysis in the central nervous 
system. However, activation of vascular postsynaptic receptors 
causes both vasoconstriction (through activation of the α2-
adrenoceptors on the vascular smooth muscle cells) and 
vasodilatation (through the activation of α2-adrenoceptors 
on the endothelial cells). Recently, it has been reported that 
systemically administered DMT caused vasoconstriction with 
doses lower than the clinically recommended dose [7].
    Since vasopressin is one of the principal vasoconstrictors for 
human vessels and the mechanisms of its vasoconstrictive effect 
are likely different than the mechanisms for DMT-induced 
vasoconstriction, there is a possibility of a synergic effect with 
vasopressin and DMT in human arteries. Despite extensive 
use of both drugs to induce vasoconstriction, there is scant 
information available in their postoperative management for 
CABG. In this study, we hypothesized that DMT can enhance 
vasopressin-induced contraction in human gastroepiploic 
arteries (GEA). Moreover, we evaluated the effect of vasopressin 
on DMT-induced contraction in human GEA.
Materials and Methods
    This study was approved by the Institutional Review Board of 
the University Hospital. After informed consent was obtained, 
discarded GEAs were obtained from patients who underwent 
subtotal gastrectomy (n = 10, 43-74 yr). GEA segments were 
collected and immediately delivered to the laboratory. The 
tissues were then placed in an oxygenated physiologic salt 
solution (PSS) that was maintained at 4
oC. Fat and connective 
tissues were carefully removed, and vascular rings (2-3 mm 
length) were prepared. The rings were then suspended on wires 
in organ baths filled with PSS. Four segments in separate organ 
baths with PSS were run in parallel. The PSS had the following 
composition (mM/L): Na
+, 137.4; HCO
3-, 15.5; K
+, 5.9; Ca
2+, 2.6; 
H2PO
4-, 1.2; Mg
2+,1.2; Cl
-, 134.4; and glucose, 11.5. All solutions 
were continuously aerated with a mixture of 95% oxygen and 
5% carbon dioxide, the pH was adjusted to 7.3-7.4 and the 
temperature was kept at 37
oC.
    Two stainless steel hooks were introduced through the lumen 
of the vascular ring. One hook was anchored to the bottom of 
the organ bath, and the other was connected to a strain gauge 
to measure the level of isometric force. The vascular rings were 
stretched gradually to a resting tension of 2 g during a 90-120 
min equilibration period to obtain optimal tension. After the 
equilibration period, 60 mM of KCl was added to the baths and 
the contractile force was recorded. For each vessel segment, 
the greatest contraction elicited by KCl was used as a reference 
point for the remaining contractions and test contractions were 
expressed as a percentage of the reference contraction. The 
vascular rings were then washed (at least 2 times) with PSS to 
restore the basal contraction levels (i.e. vascular rings had a 
second equilibration period). 
    The following drugs were used: DMT (Orion Pharma, Turku, 
Finland) and arginine vasopressin (Sigma-Aldrich Korea, 
Youngin, Kyunggi, Korea).
Experiment 1
    To establish a dose-response curve, increasing doses of 
DMT (10
-10, 10
-9, 10
-8, 10
-7 and 10
-6 M) were added in a 
cumulative fashion to the organ baths at 3 min intervals to allow 
the vascular rings to respond to each concentration, and the 
contractile force was subsequently assessed after each addition.
    Then, vasopressin (10
-10 or 10
-9 M) was also added to the 
organ baths. After 5 min, DMT was added cumulatively in 
increasing doses (10
-10, 10
-9, 10
-8, 10
-7 and 10
-6 M) to the organ 
baths at 3 min intervals and the contractile force was assessed 
as above.
Experiment 2
    To establish a dose response for vasopressin (10
-10, 10
-9.5, 
10
-9, 10
-8.5, 10
-8, and 10
-7.5 M), it was added cumulatively to the 
organ baths at 3 min intervals and the contractile response was 
assessed after each addition. 
    Next, DMT (10
-9 or 10
-7 M) was added to the organ baths. 
After 5 min, increasing concentrations of vasopressin were then 430 www.ekja.org
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added cumulatively (10
-10, 10
-9.5, 10
-9, 10
-8.5, 10
-8, and 10
-7.5 M) 
to the organ baths at 3 min intervals, and the contraction force 
was assessed after each addition.
    Contractile responses were expressed as percentages of the 
maximum contraction in isotonic 60 mM KCl. When similar 
experiments were performed on more than one segment from 
the same patient, a mean for each patient was calculated before 
statistical analysis.
    Results were expressed as the mean ± SD. The data were 
analyzed by analysis of variance (ANOVA), followed by a 
Scheffe post-hoc test to detect individual differences and by an 
unpaired t test to compare two independent groups. Differences 
were considered significant when P < 0.05.
Results
    When DMT (10
-10, 10
-9, 10
-8, 10
-7 and 10
-6 M) was added 
cumulatively to the organ bath, the drug induced significant 
contractions at the higher concentrations (10
-7 M: 5.6 ± 4.2%, 
10
-6 M: 9.3 ± 5.7% of the maximal contraction produced by 
60 mM of KCl; P < 0.05 versus resting tension, Fig. 1). High 
concentrations of DMT significantly enhanced contractions 
induced by 10
-10 M of vasopressin (10
-7 M: 19.3 ± 4.9%, 10
-6 M: 
27.6 ± 5.8% of the maximum contraction produced by 60 mM of 
KCl; P < 0.05 versus 10
-10 M vasopressin-induced contraction, 
Fig. 2). 
    High concentrations of DMT similarly enhanced the 
contractions induced by 10
-9 M of vasopressin (10
-7 M: 80.2 
± 9.7%, 10
-6 M: 86.6 ± 11.2% of the maximum contraction 
produced by 60 mM of KCl; P < 0.05 versus 10
-9 M vasopressin-
induced contraction, Fig. 3). When vasopressin (10
-10 to 10
-7.5 
M) was added cumulatively to the vessel segments in the organ 
bath, the drug induced concentration-dependent contractions 
(Fig. 4). 
    Vasopressin did not significantly enhance contractions 
elicited by 10
-9 M concentrations of DMT (Fig. 5). However, 
lower concentrations of vasopressin (10
-10, 10
-9.5, and 10
-9 M) 
did significantly enhance contractions induced by 10
-7 M DMT 
(10
-10 M: 19.4 ± 3.8%, 10
-9.5 M: 23.4 ± 4.3%, 10
-9 M: 88.9 ± 14.1% 
of the maximum contraction produced by 60 mM of KCl; P < 0.05 
Fig. 1. Effects of increasing concentrations of dexmedetomidine 
on human gastroepiploic arterial contraction. Data are expressed 
as percent (%) contraction of dexmedetomidine to a contraction 
induced from addition of 60 mM KCl.
Fig. 2. Dexmedetomidine induced contraction of human gastro-
epiploic artery with and without vasopressin (10
-10 M). Data are 
expressed as percent (%) contraction of dexmedetomidine to a con-
traction induced from addition of 60 mM KCl. A10: contraction from 
10
-10 M of arginine vasopressin treatment, DA10: contraction from 
increasing doses of dexmedetomidine after vasopressin (10
-10 M) 
treatment, *P < 0.05 when compared with that of 10
-10 M of arginine 
vasopressin treatment. 
Fig. 3. Dexmedetomidine-induced contractions in human gastro-
epiploic arteries with and without vasopressin (10
-9 M). Data are 
expressed as percent (%) contraction of dexmedetomidine to a 
contraction induced from addition of 60 mM KCl. A9: contraction 
from 10
-9 M of arginine vasopressin treatment, DA9: contraction 
from increasing doses of dexmedetomidine after vasopressin (10
-9 M) 
treatment, *P < 0.05 when compared with that of 10
-9 M of arginine 
vasopressin treatment.431 www.ekja.org
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versus 10
-7 M DMT-induced contraction, Fig. 6).
Discussion
    In the present study, we explored the effects of DMT on vaso-
pressin-induced contractions on human GEA. In our study, 
DMT alone caused significant vasoconstriction at the higher 
concentrations (10
-7 and 10
-6 M). When high levels of DMT 
were added to vessels already exposed vasopressin, there was a 
significant enhancement of vasopressin-induced contractions, 
indicating a a synergistic effect between high levels of DMT and 
vasopressin on vasoconstriction in human GEA.
    DMT is the most selective α2-adrenoceptor agonist available 
for clinical use. Rapid injection of DMT can cause vaso  con  -
striction and result in transient hypertension through the 
activation of α2-adrenoceptors on vascular smooth muscle 
cells [8,9]. The stimulation of α1-adrenoceptors by higher 
concentrations of DMT may also contribute to vaso  constric-
tion [10,11]. This suggests that, when there is no sympathetic 
inhibition from the central nervous system (in other words, 
when there is no effects of α2-adrenoceptor agonists in the 
central nervous system), the peripheral vascular effect (i.e. vaso-
constriction) is unmasked. Talke et al. [7] reported that systemic 
administration of DMT led to peripheral vasoconstriction 
with minimal contribution from the sympatholytic effects of 
the drug. Yildiz et al. [12] suggested that DMT induced con-
centration-dependent contractions in isolated human internal 
mammary arteries by activating α2-adrenoceptors at lower 
concentrations and α1-adrenoceptors at higher concentrations. 
However, only large doses of DMT (10
-7 and 10
-6 M) in vitro 
produced significant contractions alone in human GEA in our 
experiment. Our results suggest that clinical doses (< 10
-7 M, 
0.2-0.7 μg/kg/hr) of DMT could not induce smooth muscle 
contraction in human GEA and these findings are contrary to 
previously published reports [12]. 
    When DMT was added to vessels with vasopressin already 
present, there was a significant enhancement of vasopressin-
induced contraction, but only with high doses of DMT (10
-7 and 
10
-6 M). Previous reports have suggested that α2-adenoreceptor-
induced contractions are dependent on Ca
2+ influx through 
Fig. 4. Increasing concentrations of vasopressin-induced contractions 
in human gastroepiploic arteries. Data are expressed as percent (%) 
contraction of vasopressin to a contraction induced from addition of 
60 mM KCl.
Fig. 5. Vasopressin induced contraction with and without dexmede-
tomidine (10
-9 M) in human gastroepiploic arteries. Data are 
expressed as percent (%) contraction of dexmedetomidine to a con-
traction induced from addition of 60 mM KCl. A: contraction from 
arginine vasopressin treatment, AD9: contraction from increasing 
doses of vasopressin after dexmedetomidine (10
-9 M) treatment, D9: 
contraction from 10
-9 M of dexmedetomidine treatment.
Fig. 6. Vasopressin induced contraction with and without dexme-
detomidine (10
-7 M) in the human gastroepiploic artery. Data are 
expressed as percent (%) contraction of vasopressin to a contraction 
induced from addition of 60 mM KCl. A: contraction from arginine 
vasopressin treatment, AD7: contraction from increasing doses 
of vasopressin after dexmedetomidine (10
-7 M) treatment, D7: 
contraction from 10
-7 M of dexmedetomidine treatment, *P < 0.05 
when compared with that of arginine vasopressin without dexme-
detomidine treatment.432 www.ekja.org
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the L-type voltage-dependent calcium channels [13]. In our 
experiment, DMT may have directly affected the vascular 
smooth muscles at higher concentrations (> 10
-7 M) and this is 
similar to previously reported results. Nielsen et al. suggested 
that compared to responses mediated by stimulation of 
postjunctional α1- adrenoceptors, stimulation of postjunctional 
α2- adrenoceptors relies heavily on calcium influx. Stimulation 
of postjunctional α2- adrenoceptors is, however, also coupled to 
intracellular release of calcium in isolated human subcutaneous 
resistance arteries.
    When vasopressin (10
-10 to 10
-7.5 M) was added cumulatively 
to the vessel segments in the organ bath, it produced concen-
tration-dependent contractions. DMT at 10
-7 M further 
en  hanced vasopressin-induced contractions with either 
physio  logic or clinical doses of vasopressin (10
-10, 10
-9.5, 10
-9 
M). However, 10
-9 M of DMT did not enhance vasopressin-
induced contractions even at supraclinical concentrations of 
vasopressin (> 10
-9 M). Henderson and Byron [14] reported 
that vasopressin-induced contraction has two concentration-
dependent signaling pathways. Protein kinase C activation 
and Ca
2+ entry through the voltage-dependent L-type 
calcium channels are required for picomolar vasopressin-
induced contractions. Moreover, nanomolar concentrations 
of vasopressin can acutely activate the phospholipase C and 
inositol 1,4,5-triphosphate-dependent Ca
2+ release pathways. In 
our study, vasopressin-induced contractions at picomolar levels 
was enhanced by adding 10
-7 M of DMT. Thus, this indicated 
that DMT only directly affected the vascular smooth muscles 
at higher concentrations  (> 10
-7 M) and that it produced a 
marked enhancement of the vasopressin-induced contractions 
through voltage-dependent L-type calcium channels. The 
vasoconstrictive activity of vasopressin also requires the Ca
2+ 
signaling pathway. The mechanism of vasopressin is related 
to the stimulation of V1-receptors on vascular smooth muscle 
cells and increased intracellular Ca
2+ leads to arteriolar 
vasoconstriction. The degree of vasoconstriction is dependent 
on the diameter and location of the artery. Vasopressin-induced 
contraction at nanomolar doses involved a different signaling 
pathway and the contraction effect was more potent than the 
effect seen with 10
-7 M of DMT.
    Our study has several limitations. First, several reports have 
already shown the inhibitory effect of DMT on phenylephrine-
induced contraction in GEA and in internal mammary arteries. 
This effect was related to the presynaptic α2-antagonist effect 
of DMT or the activation of α2-adrenoreceptors on endothelial 
cells, both of which can trigger the release of endothelium-
derived nitric oxide. In our study, we used isolated human 
GEA and they were denervated, i.e. without a presynaptic α2-
antagonist effect of DMT. The presynaptic α2-antagonist effect 
of DMT is important. Therefore, it is hard to directly apply our 
results to the clinical setting. Second, although all arterial grafts 
develop vasospasms, it occurs more frequently in GEA [15] and 
this led us to select isolated GEA for our experiments. However, 
there is a possibility that the results may be different in other 
vessels. Generally, vasospasm of the graft artery is related to the 
endothelial function of the graft artery. The nitric oxide and the 
endothelium-derived hyperpolarizing factor released from the 
endothelium of the graft artery may inhibit the contraction of 
the graft arteries. In this study with GEA, vasopressin-induced 
contractions overcame the effect of endothelium-derived 
relaxing factor. Finally, one should be careful to extrapolate 
the results from this study to clinical applications. There may 
be many factors that can cause graft vessel spasm in the clinic. 
These include patient and technical variables during the 
operation as well as the hormonal environment. Moreover, 
in our experiments, there was no influence from the central 
nervous system, as only the α2-adrenoceptor effect were present 
in vascular smooth muscle cells.
    In conclusion, though DMT did enhance vasopressin-
induced contraction, it did not directly lead to contraction of 
isolated human GEA at clinical doses (0.2-0.7 μg/kg/hr). At 
supraclinical doses (> 10
-7 M ), DMT significantly affected 
the vascular smooth muscle tone and enhanced vasopressin-
induced contraction. However, one should be cautious to use 
DMT for sedation of patients who underwent CABG and to use 
vasopressin in patients because our study was performed with 
denervated GEA in isolated preparations.
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